河北医科大学学报

• 论著 • 上一篇    下一篇

紫杉醇腹腔热灌注治疗晚期卵巢癌临床观察

  

  1. 1.河北医科大学第二医院妇科,河北 石家庄 050000;2. 中国人民解放军白求恩国际和平医院妇产科,
    河北 石家庄 050082;3.河北医科大学第二医院神经外科,河北 石家庄 050000
  • 出版日期:2017-12-25 发布日期:2017-12-19
  • 作者简介:李楠(1981-),女,河北石家庄人,河北医科大学第二医院主治医师,医学博士研究生,从事妇科疾病诊治研究。
  • 基金资助:
    河北省科技计划项目(152777220)

Clinical observation of hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with advanced ovarian cancer#br#

  1. .Department of Gynecology, the Second Hospital of Hebei Medical University,Shijiazhuang
    050000, China; 2.Department of Obstetrics and Gynecology, the Bethune International Peace
    Hospital of PLA, Shijiazhuang 050082, China; 3.Department of Neurosurgery, the Second
    Hospital of Hebei Medical University, Shijiazhuang 050000, China
  • Online:2017-12-25 Published:2017-12-19

摘要: [摘要]〓
〖HTH〗目的〖HTSS〗〖KG*2〗探讨肿瘤细胞减灭术(cytoreductive surgery,CRS)后紫杉醇腹腔热灌注治疗晚期卵巢癌的临床效果。
〖HTH〗方法〖HTSS〗〖KG*2〗选取晚期卵巢癌患者46例,随机分观察组和对照组各23例,观察组CRS后给予紫杉醇腹腔热灌注治疗+奥沙利铂、多西他赛静脉化疗,对照组CRS后给予奥沙利铂、多西他赛静脉化疗。比较2组治疗过程中出现的并发症与不良反应、疗效、肿瘤控制、腹腔积液控制、生活质量、无进展生存期(progressionfree survival,PFS)等指标。
〖HTH〗结果〖HTSS〗〖KG*2〗2组肿瘤控制情况和有效率差异无统计学意义(P>005);观察组腹腔积液控制情况和KPS评分情况优于对照组,无进展生存期长于对照组(P<005);2组不良反应发生率差异无统计学家意义(P>005)。
〖HTH〗结论〖HTSS〗〖KG*2〗晚期卵巢癌患者CRS术后实施紫杉醇腹腔热灌注治疗,可提高患者的腹腔积液控制、KPS评分、PFS,且不明显增加并发症与不良反应发生率。

关键词: 卵巢肿瘤, 化学疗法, 肿瘤, 局部灌注, 紫杉醇

Abstract: [Abstract]〓Objective〖HTSS〗〓To evaluate the effect of hyperthermic intraperitoneal chemotherapy with paclitaxel after cytoreductive surgery(CRS) in patients with advanced ovarian cancer.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓A total of 46 cases of advanced(stage Ⅲ-Ⅳ) ovarian cancer patients were included in our study, 23 cases in study group and 23 cases in control group randomly. The study group was treated by hyperthermic intraperitoneal chemotherapy with paclitaxel and venous chemotherapy with oxaliplatin and docetaxel regimen after CRS. While the control group was treated by venous chemotherapy with oxaliplatin and docetaxel regimen after CRS only.Clinical treatment results for toxicity and adverse reactions, curative effects, remission rate of tumor, controlled rate of ascites, quality of life, and progressionfree survival(PFS) were compared and analyzed after treatment.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓The differences of the total remission rate of tumor and curative effects between two groups were not statistically significant(P>005). The controlled rate of ascites and KPS score in the study group were all better than patients in the control group(P<005). The PFS is also beteer than that of the control group(P<005).The differences in the rate of toxicity and adverse reactions between the study group and the control group were not statistically significant(P>005).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Applying the hyperthermic intraperitoneal chemotherapy with paclitaxel to treat advanced ovarian cancer after CRS can improve the controlled rate of ascites, KPS score, PFS and with little toxicity and adverse reactions.

Key words: ovarian neoplasms, chemotherapy, cancer, regional perfusion, paclitaxel